Literature DB >> 20434879

Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study.

Diego Bellavia1, Patricia A Pellikka, Ghormallah B Al-Zahrani, Theodore P Abraham, Angela Dispenzieri, Chinami Miyazaki, Martha Lacy, Christopher G Scott, Jae K Oh, Fletcher A Miller.   

Abstract

BACKGROUND: The prognostic value of Doppler myocardial imaging, including myocardial velocity imaging, strain, and strain rate imaging, in patients with primary (AL) amyloidosis is uncertain. The aim of this longitudinal study was to identify independent predictors of survival, comparing clinical data, hematologic and cardiac biomarkers, and standard echocardiographic and Doppler myocardial imaging measures in a cohort of patients with AL amyloidosis.
METHODS: A total of 249 consecutive patients with AL amyloidosis were prospectively enrolled. The primary end point was all-cause mortality, and during a median follow-up period of 18 months, 75 patients (30%) died. Clinical and electrocardiographic data, biomarkers (brain natriuretic peptide and cardiac troponin T) and standard echocardiographic and longitudinal systolic and diastolic Doppler myocardial imaging measurements for 16 left ventricular segments were tested as potential independent predictors of survival.
RESULTS: Age (hazard ratio [HR], 1.03; P = .03), New York Heart Association class III or IV (HR, 2.47; P = .01), the presence of pleural effusion (HR, 1.79; P = .08), brain natriuretic peptide level (HR, 1.29; P = .01), ejection time (HR, 0.99; P = .13), and peak longitudinal systolic strain of the basal anteroseptal segment (HR, 1.05; P = .02) were independent predictors in the final model.
CONCLUSIONS: Multivariate survival analysis identified independent predictors of clinical outcome in patients with AL amyloidosis: New York Heart Association class III or IV, presence of pleural effusion, brain natriuretic peptide level > 493 pg/mL, ejection time < 273 ms, and peak longitudinal systolic basal anteroseptal strain less negative than or equal to -7.5% defined a high-risk group of patients. Copyright 2010 American Society of Echocardiography. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434879      PMCID: PMC4041492          DOI: 10.1016/j.echo.2010.03.027

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  19 in total

1.  Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Joseph P McConnell; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; William J Hogan; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Christopher G A McGregor; Allan S Jaffe
Journal:  Blood       Date:  2004-03-25       Impact factor: 22.113

Review 2.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

Review 3.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Authors:  Morie A Gertz; Ray Comenzo; Rodney H Falk; Jean Paul Fermand; Bouke P Hazenberg; Philip N Hawkins; Giampaolo Merlini; Philippe Moreau; Pierre Ronco; Vaishali Sanchorawala; Orhan Sezer; Alan Solomon; Giles Grateau
Journal:  Am J Hematol       Date:  2005-08       Impact factor: 10.047

4.  Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Authors:  R L Comenzo; E Vosburgh; R H Falk; V Sanchorawala; J Reisinger; S Dubrey; L M Dember; J L Berk; G Akpek; M LaValley; C O'hara; C F Arkin; D G Wright; M Skinner
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

Review 5.  Clinical-pathologic differentiation of common amyloid syndromes.

Authors:  J R Wright; E Calkins
Journal:  Medicine (Baltimore)       Date:  1981-11       Impact factor: 1.889

6.  Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival.

Authors:  A Dispenzieri; M Q Lacy; R A Kyle; T M Therneau; D R Larson; S V Rajkumar; R Fonseca; P R Greipp; T E Witzig; J A Lust; M A Gertz
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

7.  Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis.

Authors:  John L Berk; Joseph Keane; David C Seldin; Vaishali Sanchorawala; Jun Koyama; Laura M Dember; Rodney H Falk
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

8.  High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Authors:  Martha Skinner; Vaishali Sanchorawala; David C Seldin; Laura M Dember; Rodney H Falk; John L Berk; Jennifer J Anderson; Carl O'Hara; Kathleen T Finn; Caryn A Libbey; Janice Wiesman; Karen Quillen; Niall Swan; Daniel G Wright
Journal:  Ann Intern Med       Date:  2004-01-20       Impact factor: 25.391

9.  Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis.

Authors:  Jun Koyama; Patricia A Ray-Sequin; Rodney H Falk
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

10.  Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study.

Authors:  A L Klein; L K Hatle; C P Taliercio; J K Oh; R A Kyle; M A Gertz; K R Bailey; J B Seward; A J Tajik
Journal:  Circulation       Date:  1991-03       Impact factor: 29.690

View more
  29 in total

Review 1.  Role of echocardiography in cancer care.

Authors:  J K Raikhelkar; R M Steingart; C L Chen
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

2.  Role of echocardiography in assessing cardiac amyloidoses: a systematic review.

Authors:  Jun Koyama; Masatoshi Minamisawa; Yoshiki Sekijima; Koichiro Kuwahara; Tsutomu Katsuyama; Kazutoshi Maruyama
Journal:  J Echocardiogr       Date:  2019-02-11

3.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

4.  Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.

Authors:  Paolo Milani; Angela Dispenzieri; Christopher G Scott; Morie A Gertz; Stefano Perlini; Roberta Mussinelli; Martha Q Lacy; Francis K Buadi; Shaji Kumar; Mathew S Maurer; Giampaolo Merlini; Suzanne R Hayman; Nelson Leung; David Dingli; Kyle W Klarich; John A Lust; Yi Lin; Prashant Kapoor; Ronald S Go; Patricia A Pellikka; Yi L Hwa; Stephen R Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Martha Grogan
Journal:  Circ Cardiovasc Imaging       Date:  2018-05       Impact factor: 7.792

Review 5.  Cardiac amyloidosis: the heart of the matter.

Authors:  Federico Perfetto; Francesco Cappelli; Franco Bergesio; Gabriele Ciuti; Maria Cristina Porciani; Luigi Padeletti; Alberto Moggi Pignone
Journal:  Intern Emerg Med       Date:  2011-07-08       Impact factor: 3.397

6.  How to image cardiac amyloidosis.

Authors:  Rodney H Falk; Candida C Quarta; Sharmila Dorbala
Journal:  Circ Cardiovasc Imaging       Date:  2014-05       Impact factor: 7.792

7.  Cardiac amyloidosis: evolving approach to diagnosis and management.

Authors:  Hans K Meier-Ewert; Vaishali Sanchorawala; John L Berk; Frederick L Ruberg
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-12

Review 8.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

Review 9.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

10.  CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis.

Authors:  James A White; Han W Kim; Dipan Shah; Nowell Fine; Ki-Young Kim; David C Wendell; Wael Al-Jaroudi; Michele Parker; Manesh Patel; Femida Gwadry-Sridhar; Robert M Judd; Raymond J Kim
Journal:  JACC Cardiovasc Imaging       Date:  2014-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.